Share Facebook Twitter LinkedIn Pinterest Email Eli Lilly & Co.��will spend $5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. Simone Foxman reports.